Safety of viral vectors for neurological gene therapies

Current Opinion in Molecular Therapeutics

Volumn 6, Issue 5, 2004, Pages 473-481

  Maguire Zeiss, Kathleen A ^a   Federoff, Howard J ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Adeno associated virus; Dendritic cell; Factor IX; Viral vector

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA 1 ANTITRYPSIN; ALPHA INTEGRIN; AMINOTRANSFERASE; APTAMER; BLOOD CLOTTING FACTOR 9; CANCER VACCINE; DOXYCYCLINE; ETOPOSIDE; GENE PRODUCT; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HORMONE BINDING PROTEIN; INTEGRASE; INTERLEUKIN 2 RECEPTOR; LENTIVIRUS VECTOR; METALLOTHIONEIN; MIFEPRISTONE; ORNITHINE CARBAMOYLTRANSFERASE; PARVOVIRUS VECTOR; PROGESTERONE RECEPTOR; RAPAMYCIN; RETROVIRUS VECTOR; SLEEPING BEAUTY PROTEIN; TACROLIMUS; TETANUS TOXIN; TETRACYCLINE; TRANSCRIPTION FACTOR GAL4; UNCLASSIFIED DRUG; VIRUS VECTOR;

ACUTE LYMPHOCYTIC LEUKEMIA; ALZHEIMER DISEASE; AMINOTRANSFERASE BLOOD LEVEL; AMPLICON; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; DEGENERATIVE DISEASE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; ENZYME DEFECT; EPISOME; GENE EXPRESSION REGULATION; GENE SILENCING; GENE VECTOR; GLIOBLASTOMA; HEMOPHILIA; HUMAN; IDIOPATHIC DISEASE; IMMUNE RESPONSE; IMMUNOSTIMULATION; INFLAMMATION; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; REVIEW; TRANSPOSON; TREATMENT OUTCOME; VIRAL GENE THERAPY; VIRUS DNA CELL DNA INTERACTION; X CHROMOSOME LINKED DISORDER;

GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC VECTORS; HUMANS; INFLAMMATION; NERVOUS SYSTEM DISEASES; VIRUSES;

ADENO-ASSOCIATED VIRUS;

EID: 6344244642     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (107)

1. Naldini L, Blomer U, Gage FH, Trono D, Verma IM: Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA (1996) 93(21):11382-11388.
2. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D: In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science (1996) 272(5259):263-267.
3. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM: Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA (2002) 99 18):11854-11859.
4. Rabinowitz JE, Samulski RJ: Building a better vector: The manipulation of AAV virions. Virology (2000) 278 2):301-308.
5. Nakai H, Montini E, Fuess S, Storm TA, Grompe M, Kay MA: AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet (2003) 34(3):297-302.
6. Miller DG, Petek LM, Russell DW: Adeno-associated virus vectors integrate at chromosome breakage sites. Nat Genet (2004) 36(7):767-773.
7. Russell DW, Alexander IE, Miller AD: DNA synthesis and topoisomerese inhibitors increase transduction by adeno-aesociated virus vectors. Proc Natl Acad Sci USA (1995) 92(12 ):5719-5723.
8. Alexander IE, Russell DW, Miller AD: DNA-damaging agents greatly increase the transduction of nondividing cells by adeno-associated virus vectors. J Virol(1994) 68 12):8282-8287.
9. Philpott NJ, Gomos J, Falck-Pedersen E: Transgene expression after rep-mediated site-specific integration into chromosome 19. Hum Gene Ther (2004) 15(1):47-61.
10. Bakowska JC, Di Maria MV, Camp SM, Wang Y, Allen PD, Breakefield XO: Targeted transgene integration into transgenic mouse fibroblasts carrying the full-length human AAVS1 locus mediated by HSV/AAV rep+ hybrid amplicon vector. Gene Ther (2003) 10 19):1691-1702.
11. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, Bousso P et al: Gene therapy of human severe combined immunodeficiency (SCID)-XI disease. Science (2000) 288(5466):669-672.
12. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, Mclntyre E, Radford I, Villeval JL, Fraser CC, Cavazzana-Calvo M, Fischer A: A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med (2003) 348(3):255-256.
13. Schmidt M, Zickler P, Hoffmann G, Haas S, Wisslet M, Muessig A, Tisdale JF, Kuramoto K, Andrews RG, Wu T, Kiem HP et al: Polyclonal long-term repopulating stem cell clones in a primate model. Blood (2002) 100(8):2737-2743.
14. Rabbitts TH, Bucher K, Chung G, Grutz G, Warren A, Yamada Y: The effect of chromosomal translocations in acute leukemias: The LMO2 paradigm in transcription and development. Cancer Res (1999) 59(7 Suppl):1794-1798.
15. Dave UP, Jenkins NA, Copeland NG: Gene therapy insertional mutagenesis insights. Science (2004) 303(5656):333.
16. Baum C, von Kalle C, Staal FJ, Li Z, Fehse B, Schmidt M, Weerkamp F, Karlsson S, Wagemaker G, Williams DA: Chance or necessity? Insertional mutagenesis in gene therapy and its consequences. Mol Ther (2004) 9(1):5-13.
17. Ivics Z, Hackett PB, Plasterk RH, Izsvak Z: Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell (1997) 91 4):501-510.
18. Fischer SE, Wienholds E, Plasterk RH: Regulated transposition of a fish transposon in the mouse germ line. Proc Natl Acad Sci USA (2001) 98(12):6759-6764.
19. Izsvak Z, Ivics Z: Sleeping Beauty transposition: Biology and applications for molecular therapy. Mol Ther(2004) 9 2):147-156.
20. Yant SR, Meuse L, Chiu W, Ivics Z, Izsvak Z, Kay MA: Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. Nat Genet (2000) 25(1):35-41.
21. Belur LR, Frandsen JL, Dupuy A J, Ingbar DH, Largaespada DA, Hackett PB, Scott McIvor R: Gene insertion and long-term expression in lung mediated by the Sleeping Beauty transposon system. Mol Ther (2003) 8(3):501-507.
22. Montini E, Held PK, Noll M, Morcinek N, Al-Dhalimy M, Finegold M, Yant SR, Kay MA, Grompe M: In vivo correction of murine tyrosinemia type 1 by DNA-mediated transposition. Mol Ther (2002) 6(6):759-769.
23. Ortiz-Urda S, Lin Q, Yant SR, Keene D, Kay MA, Khavari PA: Sustainable correction of junctional epidermolysis bullosa via transposon-mediated nonviral gene transfer. Gene Ther (2003) 10(13):1099-1104.
24. Izsvak Z, Ivics Z, Plasterk RH: Sleeping Beauty, a wide host-range transposon vector for genetic transformation in vertebrates. J Mol Biol(2000) 302(1):93-102.
25. Yant SR, Ehrhardt A, Mikkelsen JG, Meuse L, Pham T, Kay MA: Transposition from a gutless adeno-transposon vector stabilizes transgene expression in vivo. Nat Biotechnol (2002) 20 10):999-1005.
26. Zhu Y, Dai J, Fuerst PG, Voytas DF: Controlling integration specificity of a yeast retrotransposon. Proc Natl Acad Sci USA (2003) 100(10):5891-5895.
27. Olivares EC, Hollis RP, Chalberg TW, Meuse L, Kay MA, Calos MP: Site-specific genomic integration produces therapeutic Factor IX levels in mice. Nat Biotechnol(2002) 20(11):1124-1128.
28. Groth AC, Calos MP: Phage integrases: Biology and applications. J Mol Biol (2004) 335(3):667-678.
29. Kordower JH, Bloch J, Ma SY, Chu Y, Palfi S, Roitberg BZ, Emborg M, Hantraye P, Deglon N, Aebischer P: Lentiviral gene transfer to the nonhuman primate brain. Exp Neurol (1999) 160(1 : 1-16.
30. Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, McBride J, Chen EY, Palfi S, Roitberg BZ, Brown WD et al: Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science (2000) 290 5492):767-773.
31. Thomas CE, Ehrhardt A, Kay MA: Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet (2003) 4(5):346-358.
32. Balter M: Gene therapy on trial. Science (2000) 288(5468):951-957.
33. Lowenstein PR: Virology and immunology of gene therapy, or virology and immunology of high MOI infection with defective viruses. Gene Ther (2003) 10(11):933-934.
34. Thomas CE, Birkett D, Anozie I, Castro MG, Lowenstein PR: Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain. Mol Ther (2001) 3(1 ):36-46.
35. Morral N, O'Neal WK, Rice K, Leland MM, Piedra PA, Aguilar-Cordova E, Carey KD, Beaudet AL, Langston C: Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons. Hum Gene Ther (2002) 13 1):143-154.
36. Thomas CE, Sohiedner G, Kochanek S, Castro MG, Lowenstein PR: Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: Toward realistic long-term neurological gene therapy for chronic diseases. Proc Natl Acad Sci USA (2000) 97(13):7482-7487.
37. Morral N, O'Neal W, Rice K, Leland M, Kaplan J, Piedra PA, Zhou H, Parks R J, Velji R, Aguitar-Cordova E, Wadsworth S et al: Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci USA (1999) 96 22):12816-12821.
38. Brockstedt DG, Podsakoff GM, Fong L, Kurtzman G, Mueller-Ruchholtz W, Engleman EG: Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. Clin Immunol (1999) 92(1):67-75.
39. Xiao X, Li J, McCown T J, Samulski R J: Gene transfer by adeno-associated virus vectors into the central nervous system. Exp Neurol (1997) 144(1):113-124.
40. Snyder RO, Miao C, Meuse L, Tubb J, Donahue BA, Lin HF, Stafford DW, Patel S, Thompson AR, Nichols T, Read MS et al: Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med (1999) 5(1):64-70.
41. Kessler PD, Podsakoff GM, Chen X, McQuiston SA, Colosi PC, Matelis LA, Kurtzman GJ, Byrne BJ: Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA (1996) 93(24 ):14082-14087.
42. Baekelandt V, Eggerrnont K, Michiels M, Nuttin B, Debyser Z: Optimized lentiviral vector production and purification procedure prevents immune response after transduction of mouse brain. Gene Ther (2003) 10(23):1933-1940.
43. Takahashi M, Miyoshi H, Verma IM, Gage FH: Rescue from photoreceptor degeneration in the rd mouse by human immunodeficiency virus vector-mediated gene transfer. J Virol (1999) 73(9):7812-7816.
44. Bowers WJ, Olschowka JA, Federoff HJ: Immune responses to replication-defective HSV-1 type vectors within the CNS: Implications for gene therapy. Gene Ther (2003) 10 11):941-945.
45. Corey L, Spear PG: Infections with herpes simplex viruses (1). N Engl J Med (1986) 314(11):686-691.
46. Andersen JK, Breakefield XO: Gene delivery to neruons of the adult mammalian nervous system using herpes and adenovirus vectors. In: Somatic Gene Therapy. Chang PL (Ed), CRC Press LLC, Boca Raton, FL, USA (1994).
47. Andersen JK, Garber DA, Meaney CA, Breakefield XO: Gene transfer into mammalian central nervous system using herpes virus vectors: Extended expression of bactedal lacZ in neurons using the neuron-specific enolase promoter. Hum Gene Ther (1992) 3(5):487-499.
48. Saeki Y, Ichikawa T, Saeki A, Chiocca EA, Tobler K, Ackermann M, Breakefield XO, Fraefel C: Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coil: Rescue of replication-competent virus progeny and packaging of amplicon vectors. Hum Gene Ther (1998) 9(18):2787-2794.
49. Saeki Y, Fraefel C, Ichikawa T, Breakefield XO, Chiocca EA: Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol Ther (2001) 3(4):591-601.
50. Fraefel C, Song S, Lim F, Lang P, Yu L, Wang Y, Wild P, Geller Al: Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J Virol (1996) 70 10):7190-7197.
51. Stavropoulos TA, Strathdee CA: An enhanced packaging system for helper-dependent herpes simplex virus vectors. J Virol (1998) 72(9):7137-7143.
52. Herzog RW, Yang EY, Couto LB, Hagstrom JN, Elwell D, Fields PA, Burton M, Bellinger DA, Read MS, Brinkhous KM, Podsakoff GM et al Long-term correction of canine hemophilia B by gene transfer of blood coagulation Factor IX mediated by adeno-associated viral vector. Nat Med (1999) 5(1):56-63.
53. Ge Y, Powell S, Van Roey M, McArthur JG: Factors influencing the development of an anti-Factor IX (FIX) immune response following administration of adeno-associated virus-FIX. Blood (2001) 97(12):3733-3737.
54. Kay MA, Manno CS, Ragni MV, Larson P J, Couto LB, McClelland A, Glader B, Chew A J, Tai S J, Herzog RW, Arruda V et al: Evidence for gene transfer and expression of Factor IX in haemophilia B patients treated with an AAV vector. Nat Genet (2000) 24 3):257-261.
55. Mannucci PM: The future of hemophilia treatment. Haematologica (2004) 89(7):774-776.
56. Couto LB, Parker A, Gordon J: Non-clinical AAV safety studies in rodents and nonhuman primates. Gene Therapy Workshop, La Jolla, CA, USA (2003) 6.
57. Powell JS, Ragni MV, White GC 2nd, Lusher JM, Hillman-Wiseman C, Moon TE, Cole V, Ramanathan-Girish S, Roehl H, Sajjadi N, Jelly D J, Hurst D: Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood (2003) 102(6):2038-2045.
58. Mannucci PM: Hemophilia: Treatment options in the twenty-first century. J Thromb Haemost (2003) 1 7):1349-1355.
59. Pierce G: Host and vector interactions. Gene Therapy Workshop, La Jolla, CA, USA (2003) 6.
60. Chen D, Murphy B, Sung R, Bromberg JS: Adaptive and innate immune responses to gene transfer vectors: Role of cytokines and chemokines in vector function. Gene Ther (2003) 10 11):991-998.
61. Maguire-Zeiss KA, Bowers WJ, Federoff HJ: HSV vector-mediated gene delivery to the central nervous system. Curr Opin Mol Ther (2001) 3(5):482-490.
62. Naumann U, Schmidt F, Wick W, Frank B, Weir S, Gillissen B, Daniel P, Weller M: Adenoviral natural born killer gene therapy for malignant glioma. Hum Gene Ther (2003) 14(13 ):1235-1246.
63. Dewey RA, Morrissey G, Cowsill CM, Stone D, Bolognani F, Dodd NJ, Southgate TD, Klatzmann D, Lassmann H, Castro MG, Lowenstein PR: Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials. Nat Med (1999) 5(11):1256-1263.
64. Benner EJ, Mosley RL, Destache CJ, Lewis TB, Jackson-Lewis V, Gorantla S, Nemachek C, Green SR, Przedborski S, Gendelman HE: Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA (2004) 101 25):9435-9440.
65. Willis RA, Bowers WJ, Turner MJ, Fisher TL, Abdul-Alim CS, Howard DF, Federoff HJ, Lord EM, Frelinger JG: Dendritic cells transduced with HSV-1 amplicons expressing prostate-specific antigen generate antitumor immunity in mice. Hum Gene Ther (2001) 12 15):1867-1879.
66. Hocknell PK, Wiley RD, Wang X, Evans TG, Bowers WJ, Hanke T, Federoff HJ, Dewhurst S: Expression of human immunodeficiency virus type 1 gp120 from herpes simplex virus type 1-derived amplicons results in potent, specific, and durable cellular and humoral immune responses. J Virol (2002) 76(11):5565-5580.
67. Gupta N: Current status of viral gene therapy for brain tumours. Expert Opin Investig Drugs (2000) 9(4 ):713-726.
68. Herrlinger U, Jacobs A, Quinones A, Woiciechowsky C, Sena-Esteves M, Rainov NG, Fraefet C, Breakefield XO: Helper virus-free herpes simplex virus type 1 amplicon vectors for granulocyte-macrophage colony-stimulating factor-enhanced vaccination therapy for experimental glioma. Hum Gene Ther(2000) 11 10):1429-1438.
69. Bowers WJ, Mastrangelo MA, Stanley HA, Casey AE, Mile LJ, Federoff HJ: HSV amplicon-mediated Aβ vaccination in Tg2576 mice: Differential antigen-specific immune responses. Neurobiol Aging (2004):doi:10.1016/j.neurobiolaging.2004.04.006.
70. Gossen M, Bujard H: Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA (1992) 89(12):5547-5551.
71. Belshaw PJ, Ho SN, Crabtree GR, Schreiber SL: Controlling protein association and subcellular localization with a synthetic ligand that induces heterodimerization of proteins. Proc Natl Acad Sci USA (1996) 93(10):4604-4607.
72. Wang Y, DeMayo FJ, Tsai SY, O'Malley BW: Ligand-inducible and liver-specific target gene expression in transgenic mice. Nat Biotechnol (1997) 15(3):239-243.
73. Wang Y, Xu J, Pierson T, O'Malley BW, Tsai SY: Positive and negative regulation of gene expression in eukaryotic cells with an inducible transcriptional regulator. Gene Ther (1997) 4 5):432-441.
74. Vegeto E, Allan GF, Schrader WT, Tsai MJ, McDonnell DP, O'Malley BW: The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. Cell (1992) 69(4):703-713.
75. Garcia T, Benhamou B, Gofflo D, Vergezac A, Philibert D, Chambon P, Gronemeyer H: Switching agonistic, antagonistic, and mixed transcdptional responses to 11 IS-substituted progestins by mutation of the progesterone receptor. Mol Endocrinol(1992) 6 12):2071-2078.
76. Toniatti C, Bujard H, Cortese R, Ciliberto G: Gene therapy progress and prospects: Transcription regulatory systems. Gene Ther (2004) 11(8):649-657.
77. Oligino T, Poliani PL, Wang Y, Tsai SY, O'Malley BW, Fink D J, Glorioso JC: Drug inducible transgene expression in brain using a herpes simplex virus vector. Gene Ther(1998) 5(4 ):491-496.
78. Nordstrom JL: The antiprogestin-dependent GeneSwitch system for regulated gene therapy. Steroids (2003) 68 10-13):1085-1094.
79. Haberman RP, McCown TJ: Regulation of gene expression in adeno-associated virus vectors in the brain. Methods (2002) 28(2):219-226.
80. Harvey DM, Caskey CT: Inducible control of gene expression: Prospects for gene therapy. Curr Opin Chem Biol (1998) 2(4):512-518.
81. Baron U, Bujard H: Tet repressor-based system for regulated gene expression in eukaryotic cells: Principles end advances. Methods Enzymol (2000) 327:401-421.
82. Urlinger S, Baron U, Thellmann M, Hasan MT, Bujard H, Hiilen W: Exploring the sequence space for tetracycline-dependent transcriptional activators: Novel mutations yield expanded range and sensitivity. Proc Natl Acad Sci USA (2000) 97 14):7963-7968.
83. Lamartina S, Roscilli G, Rinaudo CD, Sporeno E, Silvi L, Hillen W, Bujard H, Cortese R, Ciliberto G, Toniatti C: Stringent control of gene expression in vivo by using novel doxycycline-dependent transactivators. Hum Gene Ther(2002) 13 2):199-210.
84. kid-based transcription regulatory switch that displays no basal activity, good inducibility, and high responsiveness to doxycycline in mice and non-human primates. Mol Ther (2003) 7(2):271-280.
85. Salucci V, Scarito A, Aurisicchio L, Lamartina S, Nicolaus G, Grampaoli S, Gonzalez-Paz O, Toniatti C, Bujard H, Hillen W, Ciliberto G, Palombo F: Tight control of gene expression by a helper-dependent adenovirus vector carrying the rtTA2(s)-M2 tetracycline transactivator and repressor system. Gene Ther (2002) 9(21):1415-1421.
86. Mizuguchi H, Xu ZL, Sakurai F, Mayumi T, Hayakawa T: Tight positive regulation of transgene expression by a single adenovirus vector containing the rtTA and tTS expression cassettes in separate genome regions. Hum Gene Ther (2003) 14(13):1265-1277.
87. Xu ZL, Mizuguchi H, Mayumi T, Hayakawa T: Regulated gene expression from adenovirus vectors: A systematic comparison of various inducible systems. Gene (2003) 309(2):145-151.
88. Zerby D, Sakhuja K, Reddy PS, Zimmerman H, Kayda D, Ganesh S, Pattison S, Brann T, Kadan MJ, Kaleko M, Connelly S: In vivo ligand-inducible regulation of gene expression in a gutless adenoviral vector system. Hum Gene Ther (2003) 14(8):749-761.
89. Chtarto A, Bender HU, Hanemann CO, Kemp T, Lehtonen E, Levivier M, Brotchi J, Velu T, Tenenbaum L: Tetracycline-inducible transgene expression mediated by a single AAV vector. Gene Ther (2003) 10(1):84-94.
90. Favre D, Blouin V, Provost N, Spisek R, Porrot F, Bohl D, Marme F, Cherel Y, Salvetti A, Hurtrel B, Heard JM et al: Lack of an immune response against the tetracycline-dependent transactivator correlates with long-term doxycycline-regulated transgene expression in nonhuman primates after intramuscular injection of recombinant adeno-associated virus. J Virol (2002) 76(22 ):11605-11611.
91. Latta-Mahieu M, Rolland M, Caillet C, Wang M, Kennel P, Mahfouz I, Loquet I, Dedieu JF, Mahfoudi A, Trannoy E, Thuillier V: Gene transfer of a chimeric trans-activator is immunogenic and results in short-lived transgene expression. Hum Gene Ther (2002) 13 13):1611-1620.
92. Wang Y, O'Malley BW Jr, Tsai SY, O'Malley BW: A regulatory system for use in gene transfer. Proc Natl Acad Sci USA (1994) 91(17):8180-8184.
93. Abruzzese RV, Godin D, Mehta V, Perrard JL, French M, Nelson W, Howell G, Coleman M, O'Malley BW, Nordstrom JL: Ligand-dependent regulation of vascular endothelial growth factor and erythropoietin expression by a plasmid-based autoinducible GeneSwitch system. Mol Ther (2000) 2(3):276-287.
94. Nordstrom JL: Antiprogestin-controllable transgene regulation in vivo. Curr Opin Biotechnol (2002) 13 5):453-458.
95. Sarkar NN: Mifepristone: Bioavailability, pharmacokinetics and use-effectiveness. Eur J Obstet Gynecol Reprod Biol (2002) 101(2):113-120.
96. Molin M, Shoshan MC, Ohman-Forslund K, Linder S, Akusjarvi G: Two novel adenovirus vector systems permitting regulated protein expression in gene transfer experiments. J Virol (1998) 72 10):8358-8361.
97. Pollock R, Clackson T: Dimerizer-regulated gene expression. Curr Opin Biotechnol (2002) 13(5):459-467.
98. Rossi FM, Blau HM: Recent advances in inducible gene expression systems. Curr Opin Biotechnol (1998) 9 5):451-456.
99. Kahan BD: Sirolimus: A comprehensive review. Expert Opin Pharmacother (2001 ) 2(11):1903-1917.
100. Amara JF, Clackson T, Rivera VM, Guo T, Keenan T, Natesan S, Pollock R, Yang W, Courage NL, Holt DA, Gilman M: A versatile synthetic dimerizer for the regulation of protein-protein interactions. Proc Natl Acad Sci USA (1997) 94(20 ):10618-10623.
101. Chong H, Ruchatz A, Clackson T, Rivera VM, Vile RG: A system for small-molecule control of conditionally replication-competent adenoviral vectors. Mol Ther (2002) 5(2):195-203.
102. Auricchio A, Gao GP, Yu QC, Raper S, Rivera VM, Clackson T, Wilson JM: Constitutive and regulated expression of processed insulin following in vivo hepatic gene transfer. Gene Ther (2002) 9(14):963-971.
103. Auricchio A, Rivera VM, Clackson T, O'Connor EE, Maguire AM, Tolentino MJ, Bennett J, Wilson JM: Pharmacological regulation of protein expression from adeno-associated viral vectors in the eye. Mol Ther(2002) 6(2):238-242.
104. Chyung YH, Peng PD, Kay MA: System for simultaneous tissue-specific and disease-specific regulation of therapeutic gene expression. Hum Gene Ther (2003) 14(13): 1255-1264.
105. Do Thi NA, Saillour P, Ferrero L, Dedieu JF, Mallet J, Paunio T: Delivery of GDNF by an E1,E3/E4 deleted adenoviral vector and driven by a GFAP promoter prevents dopaminergic neuron degeneration in a rat model of Parkinson's disease. Gene Ther (2004) 11(9):746-756.
106. Azzouz M, Martin-Rendon E, Barber RD, Mitrophanous KA, Carter EE, Rohll JB, Kingsman SM, Kingsman AJ, Mazarakis ND: Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease. J Neurosci (2002) 22(23):10302-10312.
107. Wu K, Meyers CA, Guerra NK, King MA, Meyer EM: The effects of rAAV2-mediated NGF gene delivery in adult and aged rats. Mol Ther (2004) 9(2):262-269.